India, July 22 -- Polyrizon Ltd. (PLRZ) surged 53.37 percent to $1.39 on Tuesday after announcing promising preclinical results for its PL-14 Allergy Blocker, part of the company's proprietary Capture & Contain platform.
Shares opened at $1.06 and traded between $1.03 and $1.87, compared to the previous close of $0.91 on the Nasdaq. The stock's 52-week range is $0.55 to $1,200. Volume spiked to 89.48 million shares, well above the average of 4.93 million.
The study, conducted with the University of Parma, showed PL-14 achieved over 60 percent deposition in the nasal vestibule the primary site of early allergen contact supporting its potential as a barrier-forming treatment for allergic rhinitis.
For comments and feedback contact: editori...